XDH and hyperuricemia: The three XOR inhibitors currently used for the treatment of hyperuricemia and gout are thought to also suppress the production of ROS and NO and may be able to expand the range of indications for the treatment of conditions such as ischemia-reperfusion injury and atherosclerosis in the future.